Alkermes (ALKS) Change in Accured Expenses (2010 - 2026)
Alkermes' (ALKS) quarterly Change in Accured Expenses came in at -$119.5 million in Q1 2026, down 7007.2% year-on-year from $1.7 million in Q1 2025, and down 429.32% on a QoQ basis from -$22.6 million in Q4 2025.
Alkermes (ALKS) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Change in Accured Expenses data on file, last reported at -$119.5 million in Q1 2026.
- On a quarterly basis, Change in Accured Expenses fell 7007.2% year-over-year to -$119.5 million in Q1 2026; TTM through Mar 2026 was -$112.5 million, a 348.91% decrease from a year earlier, with the FY2025 full-year figure at $5.3 million, down 37.21% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$119.5 million, down from -$22.6 million in the prior quarter.
- Over the last five years, Change in Accured Expenses for ALKS reached as high as $91.4 million in Q4 2024 and fell as low as -$119.5 million in Q1 2026.
- Historically, Change in Accured Expenses has averaged -$4.1 million across 5 years, with a median of $1.8 million in 2022.
- Across the five-year window, Change in Accured Expenses tumbled 39101.72% in 2022 and surged 4356.75% in 2024, its largest moves.
- Year by year, Change in Accured Expenses stood at $6.3 million in 2022, then tumbled by 67.65% to $2.1 million in 2023, then jumped by 4356.75% to $91.4 million in 2024, then plunged by 124.69% to -$22.6 million in 2025, then plunged by 429.32% to -$119.5 million in 2026.
- Per Business Quant data, the three most recent Change in Accured Expenses figures were -$119.5 million in Q1 2026, -$22.6 million in Q4 2025, and -$28.2 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -144.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -234.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -12.70 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -14.30 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | -119.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -119.47 Mn |
| Mar 31, 2026 | -119.47 Mn |
| Dec 31, 2025 | -22.57 Mn |
| Dec 31, 2025 | -22.57 Mn |
| Sep 30, 2025 | -28.25 Mn |
| Sep 30, 2025 | -28.25 Mn |
| Jun 30, 2025 | 57.79 Mn |
| Jun 30, 2025 | 57.79 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Mar 31, 2025 | -1.68 Mn |
| Dec 31, 2024 | 91.41 Mn |
| Dec 31, 2024 | 91.41 Mn |
| Sep 30, 2024 | -83.99 Mn |
| Sep 30, 2024 | -83.99 Mn |
| Jun 30, 2024 | 39.46 Mn |
| Jun 30, 2024 | 39.46 Mn |
| Mar 31, 2024 | -38.45 Mn |
| Mar 31, 2024 | -38.45 Mn |
| Dec 31, 2023 | 2.05 Mn |
| Dec 31, 2023 | 2.05 Mn |